Polycystic ovary syndrome (PCOS) affects roughly 8-13% of women of reproductive age and is closely linked to obesity, insulin resistance, anovulation, and infertility. No GLP-1 receptor agonist is FDA-approved for PCOS in 2026, but viral "Ozempic baby" stories — unplanned pregnancies in women previously thought infertile — have made GLP-1s a common off-label PCOS therapy. The evidence base is small but maturing: most randomized data come from a single Slovenian group (Jensterle, Janez, Salamun) running short pilot trials of liraglutide and semaglutide; the foundational menstrual-cyclicity signal comes from Elkind-Hirsch's 2008 exenatide-metformin trial; and a handful of 2024-2025 meta-analyses and narrative reviews have tried to synthesize the heterogeneous literature. The Endocrine Society's 2013 PCOS clinical practice guideline (Legro) remains the canonical anchor: weight loss restores ovulation regardless of how the weight is lost, which is the central mechanism by which GLP-1s appear to improve PCOS fertility outcomes.
Ranked papers
#1
Legro RS, Arslanian SA, Ehrmann DA, et al. · J Clin Endocrinol Metab · 2013
Primary endpoint: Clinical practice guideline (diagnostic + therapeutic recommendations)
The Endocrine Society's 2013 PCOS clinical practice guideline remains the canonical reference framework for PCOS management in 2026. It explicitly recommends weight loss through lifestyle modification as first-line therapy for overweight or obese women with PCOS, noting that even modest 5-10% weight reductions restore ovulation and improve fertility in a majority of patients. Critically, the guideline establishes that ovulation recovery follows weight loss independent of the specific intervention used — the mechanistic foundation later invoked to justify off-label GLP-1 receptor agonist use in obese PCOS patients.
PMID 24151290 ↗DOI 10.1210/jc.2013-2350 ↗
#2
Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. · J Clin Endocrinol Metab · 2008
Primary endpoint: Menstrual frequency and ovulation rate at 24 weeks
Elkind-Hirsch's 2008 trial is the foundational randomized study of a GLP-1 receptor agonist in PCOS. Sixty overweight women with PCOS were randomized to exenatide alone, metformin alone, or combination therapy for 24 weeks. Menstrual frequency improved most with combination therapy (combined improved menstrual frequency 2.7-fold versus baseline), and ovulation rate measured by midluteal progesterone was 86% with combination versus 24% on metformin and 50% on exenatide alone. This is the first randomized signal that a GLP-1 receptor agonist restores ovulation in PCOS — the citation that anchors nearly every later PCOS-GLP-1 review.
PMID 18460557 ↗DOI 10.1210/jc.2008-0115 ↗
#3
Salamun V, Jensterle M, Janez A, et al. · Eur J Endocrinol · 2018
Primary endpoint: Pregnancy rate per embryo transfer following IVF
Salamun's 2018 trial is the only randomized study with a hard fertility endpoint — IVF pregnancy rate — comparing a GLP-1 receptor agonist to standard care. Twenty-eight obese PCOS women with poor response to prior ART were randomized to 12 weeks of low-dose liraglutide plus metformin versus metformin alone before IVF. The liraglutide-metformin arm achieved a pregnancy rate per embryo transfer of 85.7% versus 28.6% on metformin alone. Cumulative live-birth rate also favored liraglutide. The trial is small but is the most-cited justification for GLP-1 pretreatment ahead of IVF in obese PCOS patients.
PMID 29703793 ↗DOI 10.1530/EJE-18-0175 ↗
#4
Jensterle M, Salamun V, Kocjan T, et al. · J Ovarian Res · 2015
Primary endpoint: Body weight change at 12 weeks
This 12-week three-arm pilot trial from the Slovenian Jensterle/Janez group randomized 45 obese PCOS women to liraglutide 1.2 mg daily, roflumilast 500 mcg daily, or metformin 1,000 mg twice daily. Liraglutide produced the largest weight loss (~3.8 kg) versus minimal loss on metformin. The trial is one of the first head-to-head comparisons of a GLP-1 receptor agonist against the standard PCOS metformin baseline and established the proof-of-concept that GLP-1s outperform metformin for the obesity component of PCOS — although both arms remained small and ovulation was not a primary endpoint.
PMID 26032655 ↗DOI 10.1186/s13048-015-0161-3 ↗
#5
Wang FF, Wu Y, Zhu YH, et al. · Obes Rev · 2018
Primary endpoint: Body weight reduction across pharmacotherapies (network meta-analysis)
Wang's 2018 network meta-analysis pooled randomized trials of pharmacologic weight-loss interventions in PCOS, ranking liraglutide and exenatide alongside orlistat, sibutramine, and metformin. GLP-1 receptor agonists produced the largest weight reductions and the most consistent reductions in BMI, waist circumference, and HOMA-IR. The analysis is heavily weighted by the small Jensterle and Elkind-Hirsch trials but is the first formal evidence-synthesis ranking GLP-1s above metformin for the obesity component of PCOS — a finding repeatedly cited to support off-label use.
PMID 30066361 ↗DOI 10.1111/obr.12720 ↗
#6
Cena H, Chiovato L, Nappi RE · J Clin Endocrinol Metab · 2020
Primary endpoint: Mechanistic and clinical narrative review (no primary endpoint)
Cena's 2020 narrative review in J Clin Endocrinol Metab is the most-cited synthesis of the mechanistic case for GLP-1 receptor agonists in PCOS-related infertility. It frames GLP-1 effects on hyperinsulinemia, androgen excess, hypothalamic-pituitary-gonadal axis signaling, and direct ovarian GLP-1 receptor expression — alongside indirect effects mediated by weight loss. The review is honest about evidence quality: small trials, short duration, no FDA approval, and ovulation/fertility data limited to two RCTs at the time. Remains the canonical mechanistic citation in PCOS-GLP-1 review articles.
PMID 32442310 ↗DOI 10.1210/clinem/dgaa285 ↗
#7
Liao M, Li X, Zhang H, et al. · Endocrine · 2024
Primary endpoint: Anthropometric, hormonal, and proteomic changes at 12 weeks
This 2024 Chinese RCT randomized 64 overweight PCOS women to a GLP-1 receptor agonist plus metformin versus combined oral contraceptive (cyproterone acetate/ethinyl estradiol) plus metformin for 12 weeks. The GLP-1 arm produced significantly greater weight loss, waist-circumference reduction, and HOMA-IR improvement, while the COC arm produced larger reductions in serum testosterone. Plasma proteomic analysis identified distinct biological pathways — inflammation and adipogenesis — modulated by GLP-1 but not COC. Notable as one of the few RCTs comparing GLP-1 head-to-head against standard PCOS hormonal therapy rather than placebo or metformin.
PMID 37653215 ↗DOI 10.1007/s12020-023-03487-4 ↗
#8
Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, et al. · J Diabetes Complications · 2024
Primary endpoint: Pooled weight, BMI, HOMA-IR, testosterone, SHBG, and menstrual frequency
Morais 2024 is the most recent comprehensive meta-analysis of GLP-1 receptor agonists in PCOS, pooling roughly a dozen RCTs of liraglutide, exenatide, and semaglutide. Pooled effects: ~3 kg greater weight loss versus comparator, BMI reduction ~1.5 kg/m², HOMA-IR improvement, and modest reductions in free androgen index. Menstrual frequency improved across studies though heterogeneity was high. The analysis confirms the direction and magnitude of effect but underscores persistent limitations — small sample sizes, short follow-up, predominantly Slovenian and Chinese trials, and almost no live-birth or sustained ovulation data.
PMID 39178623 ↗DOI 10.1016/j.jdiacomp.2024.108834 ↗
#9
Sola-Leyva A, Pathare ADS, Apostolov A, et al. · Acta Obstet Gynecol Scand · 2025
Primary endpoint: Mechanistic review of endometrial and implantation effects
Sola-Leyva's 2025 review tackles a downstream fertility question rarely addressed in PCOS-GLP-1 trials: do GLP-1 receptor agonists affect endometrial receptivity and implantation? The authors synthesize evidence that GLP-1 receptors are expressed in endometrial tissue and that GLP-1 signaling may modulate endometrial inflammation, decidualization, and vascular remodeling. Effect direction in humans remains unclear, with both potentially beneficial (reduced inflammation, improved vascularization) and potentially harmful (interference with normal implantation signaling) pathways proposed. Underscores the need to wash GLP-1s out before conception and the unresolved mechanistic uncertainty driving "Ozempic baby" anecdotes.
PMID 39696822 ↗DOI 10.1111/aogs.15010 ↗
#10
Finkle J, Brost BC · Obstet Gynecol · 2025
Primary endpoint: Clinical review of fertility and pregnancy implications
Finkle and Brost's 2025 Obstetrics & Gynecology review is the most cited obstetrics-society-aligned synthesis of GLP-1 use in infertility and pregnancy. It frames the "Ozempic baby" phenomenon — unplanned pregnancies in women previously thought infertile — as a real but underquantified signal, summarizes the limited PCOS efficacy data, and provides explicit guidance for prescribers: counsel patients about restored fertility, recommend contraception, wash out GLP-1s at least 2 months before planned conception, and discontinue immediately if pregnancy occurs. The clearest clinical-practice document linking the PCOS-GLP-1 evidence base to actual prescribing decisions.
PMID 39847778 ↗DOI 10.1097/AOG.0000000000005825 ↗
About this list
We curate ranked, citation-anchored PubMed paper lists for the most-searched questions in obesity medicine. Every citation on this page was checked against PubMed on 2026-05-28. Each paper card links directly to PubMed and to ClinicalTrials.gov where applicable.
Browse our full index of research lists or our long-form research articles.